1 / 42

Highlights of the Day II:<br />SARCOMA<br />“The not so Old and the New”

Highlights of the Day II:<br />SARCOMA<br />“The not so Old and the New”. Presented By Dennis Priebat at 2014 ASCO Annual Meeting. Sarcoma Highlights:. Presented By Dennis Priebat at 2014 ASCO Annual Meeting.

oliana
Download Presentation

Highlights of the Day II:<br />SARCOMA<br />“The not so Old and the New”

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Highlights of the Day II:<br />SARCOMA<br />“The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  2. Sarcoma Highlights: Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  3. Long-term Disease Control of Advanced Gastrointestinal Stromal Tumors (GIST) <br />with Imatinib (IM): 10-year Outcomes from SWOG Phase III Intergroup Trial S0033 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  4. S0033 Study Design: Randomized Phase III trial of Imatinib at 400 vs. 800 mg/d for Advanced KIT-expressing GIST Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  5. S0033 Long-Term Study Events Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  6. Slide 6 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  7. Analysis of On-Study and <br />Post-Progression Therapies <br />(i.e. after progression on imatinib) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  8. Analysis of Post-Progression Therapies <br />(i.e. after progression on imatinib) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  9. Summary S0033: Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  10. Summary S0033: Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  11. Unmet Treatment Challenges for the Expanding GIST Landscape Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  12. AngioTax-Plus trial: a randomized phase II trial assessing the activity of weekly paclitaxel (WP) +/- bevacizumab (B) in advanced angiosarcoma (AS) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  13. Angiosarcoma Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  14. Patients & methods Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  15. Treatments Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  16. Baseline characteristics Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  17. Activity - Efficacy endpoints Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  18. Grade 3/4 Toxicities Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  19. Drug-related SAE Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  20. Summary Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  21. Proof of Concept Trials for Patients With Advanced Pigmented Villonodular Synovitis(PVNS): Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  22. Pigmented Villonodular Synovitis (PVNS)<br />Tenosynovial Giant Cell Tumor (TGCT) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  23. Pigmented Villonodular Synovitis (PVNS) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  24. <br /> A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  25. Study Design Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  26. Patient Characteristics: Safety Population (n=23) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  27. Duration of Treatment (DOT), April 2014 data cutoff:<br />Median 256 days (range 21-585 days) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  28. Tumor Volume Score (TVS) Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  29. PLX3397 Clinical Efficacy in PVNS<br />Rapid and Sustained Tumor Size Reductions in Most Cases Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  30. PLX3397 Clinical Efficacy in PVNS Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  31. Safety: PVNS Expansion Cohort AEs<br />n = 23 Safety Population Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  32. Treatment-Related AEs ≥ Grade 3 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  33. Slide 33 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  34. Slide 34 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  35. Slide 35 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  36. Slide 36 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  37. Slide 37 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  38. Slide 38 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  39. Slide 39 Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  40. CSF1R TKI or moAb for PVNS Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  41. CSF1R TKI or moAb for PVNS Presented By Dennis Priebat at 2014 ASCO Annual Meeting

  42. Take Home Points Presented By Dennis Priebat at 2014 ASCO Annual Meeting

More Related